Intersect nabs $30M for drug/device combo

Intersect ENT nailed down $30 million in new Series D funding that attracted major investor interest from Medtronic ($MDT) and a number of other high-profile players. Executives aren't wasting any time, and they are using the cash infusion to rapidly accelerate commercial expansion plans for the company's quarter-sized implants to treat chronic sinusitis. Story